R&D News | pharmaphorum

Wednesday 28 October 2026

News

News

BMS eyes filings for myeloma 'celmod' iberdomide

BMS eyes filings for myeloma 'celmod' iberdomide

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

News

AI representation

MSD's $349m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Jacopo Andreose, Angelini Pharma's chief executive

Angelini taps Sovargen for epilepsy drug in $550m deal

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

News

After internal setbacks, Pfizer buys obesity player Metsera

After internal setbacks, Pfizer buys obesity player Metsera

Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.